NCT Number: NCT02127580
Balloon Expandable Transcatheter Aortic Valve Implantation Without Predilation of the Aortic Valve
There is limited experience for the balloon expandable THV (transcatheter heart valve) on the need for predilation (ballon aortic valvuloplasty, BAV). Therefore we aim to verify results of a small case series published by Wendler et. al. to examine hard endpoints such as the incidence of cerebrovascular complications, paravalvular leakage and operative outcomes in a multicenter registry.
We aim to compare the implantation of balloon expandable transcatheter heart valves with or without predilation with respect to procedural outcomes (VARC2).
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Observational
Primary location
Clinic for Cardiac Surgery Karlsruhe, Karlsruhe, Baden-Wurttemberg, Germany
About this study
Prior to the deployment of transcatheter heart valves (THV), balloon aortic valvuloplasty (BAV) is usually performed under rapid right ventricular pacing (burst >180 bpm) with the induction of a functional cardiac arrest for up to 30 seconds. Aortic valve predilation is aiming at facilitating the crossing of the aortic annulus, accurate valve positioning and does also provide information on the anatomy of the valve complex. However, BAV has been shown to have a number of potentially detrimental effects, such as:
- Functional cardiac arrest induced by rapid pacing leads to transient coronary, cerebral, and renal ischemia.
- In patients with a reduced left ventricular ejection fraction (LVEF), prolonged cardiac depression after rapid pacing is observed and may result in hemodynamic failure and systemic inflammatory response syndrome (SIRS). Both are associated with a high periprocedural mortality.
- BAV has been identified as a major source of thrombotic and valvular material and increases the risk for coronary obstruction with subsequent myocardial infarction and stroke.
- The local trauma in the left-ventricular outflow tract caused by BAV may potentially contribute to aortic root rupture.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Patients with an indication for TAVI as to the Edwards THV IFU
- Eligible for TABI with AND without BAV
- Signed informed consent
Exclusion criteria
- Logistic EuroSCORE I >50%
- Mitral or tricuspid valvular insufficiency (> grade II)
- Previous aortic valve replacement
- Uncontrolled atrial fibrillation
- Left ventricular or atrial thrombus by echocardiography
- Recent cerebrovascular event (within the last 3 months)
- High probability of non-adherence to the follow-up requirements (due to social, psychological or medical reasons)
Treatment and study plan
without BAV
ProcedurePrimary outcomes
-
VARC2 criteria
Time frame: 3 months
comparison of the implantation of balloon expandable transcatheter heart valves with or without predilation with respect to procedural outcomes (VARC2).
Sponsors and collaborators
Lead sponsor
Institut für Pharmakologie und Präventive Medizin
Network
Registry information
Official study title
Balloon Expandable Transcatheter Aortic Valve Implantation Without Predilation of the Aortic Valve (EASE-IT) A Two-armed Registry
Acronym: EASE-IT
Important dates
- Study start
- 2014
- Primary completion
- 2016
- Study completion
- 2016
- First posted
- Apr 30, 2014
- Registry last updated
- Apr 27, 2018
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
TAVI Without Balloon Predilatation (of the Aortic Valve ) SAPIEN 3
NCT02729519
Aortic Valve Disease, Aortic Valve Stenosis
Montpellier, France
View Trial DetailsTAVI in LOW RISK in the REAL WORLD
NCT07605780
Aortic Valve Disease, Aortic Valve Stenosis
Brescia, BS, Italy
View Trial DetailsEMPagliflozin After Aortic Valve Replacement
NCT06171802
Aortic Valve Disease, Aortic Valve Stenosis
Copenhagen, Denmark
View Trial DetailsRoutine Versus Selective Protamine Administration to Reduce Bleeding Complications After Transcatheter Aortic Valve Implantation (POPular ACE TAVI)
NCT05774691
Aortic Valve Disease, Aortic Valve Stenosis
Aalst, Belgium
View Trial Details